logo-loader
RNS
viewAmphion Innovations PLC

Suspension - Amphion Innovations Plc

/**/ .k{size:595.3pt 841.9pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;}div.k{}p.q{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Arial","sans-serif";line-height:12.0pt;text-autospace:none}span.o{font-size:10.0pt;font-family:"Helv","sans-serif";color:black}p.r{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.m{font-size:10.0pt;font-family: "Helv","sans-serif";color:black} /**/
RNS Number : 8824D
AIM
01 July 2019
 

NOTICE

 

01/07/2019 7:30am

 

TEMPORARY SUSPENSION OF TRADING ON AIM

 

AMPHION INNOVATIONS PLC

 

Trading on AIM for the under-mentioned securities has been temporarily suspended from 01/07/2019 7:30am, pending publication of the company's annual report and accounts.

 

ORDINARY SHARES OF 1P EACH, FULLY PAID (B0DJNP9) (GB00B0DJNP99)

 

If you have any queries relating to the above, please contact the company's nominated adviser on +44 (0)20 7886 2500.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
EXCEADKPASLNEFF

Quick facts: Amphion Innovations PLC

Price: 0.15

Market: AIM
Market Cap: £314.96 k
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio. Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s...

on 10/10/17